Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin

Piergiorgio Zuccaro, Giuliana Mombelli, Laura Calabresi, Damiano Baldassarre, Ilaria Palmi, Cesare R. Sirtori

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Statin therapy, although generally well tolerated, leads not infrequently to significant subjective and at times objective adverse effects (AEs), mainly of a muscular nature. The genetic background of these AEs is not clear and possibly side effects and lipid lowering efficacy may be linked. Aim of the study was a detailed evaluation of CYP450 and apolipoprotein E gene polymorphisms in two large series of age-sex matched patients with and without muscular side effects to statins. In a Clinical Institution specialised in lipid-lipoprotein disorders, 50 statin treated patients were selected, with subjective or objective statin-associated myopathy, evaluated using standardized forms. These were sex and age matched with 50 statin-treated patients from the same Clinic, without any subjective or objective complaints. DNA samples for the evaluation of CYP450 genetic polymorphisms and apo E genotypes were collected in order to assess correlations with both genetic polymorphisms and AEs, as well as with therapeutic efficacy. None of the assessed CYP450 polymorphisms appeared to be related to an increased incidence of AEs. The CYP2D6 *1/*4 and *4/4* poor metabolizer (PM) status was associated to a higher efficacy of statins metabolized by this system and, in addition, the apo E2 genotype was, in this series, linked to increased HDL-C levels after therapy. Patients with statin associated myopathy are not characterized by significantly different genotypes for the CYP450s responsible for statin metabolism. On the other hand, CYP2D6 PM status is associated to an increased efficacy of statins metabolized by this system.

Original languageEnglish
Pages (from-to)310-317
Number of pages8
JournalPharmacological Research
Volume55
Issue number4
DOIs
Publication statusPublished - Apr 2007

Fingerprint

fluvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cytochrome P-450 CYP2D6
Simvastatin
Genotype
Apolipoproteins E
Muscular Diseases
Genetic Polymorphisms
Apolipoprotein E2
Lipids

Keywords

  • Apo E allele variants
  • Cholesteraemic response
  • CYP450
  • Enzyme polymophisms
  • Muscle toxicity
  • Statins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. / Zuccaro, Piergiorgio; Mombelli, Giuliana; Calabresi, Laura; Baldassarre, Damiano; Palmi, Ilaria; Sirtori, Cesare R.

In: Pharmacological Research, Vol. 55, No. 4, 04.2007, p. 310-317.

Research output: Contribution to journalArticle

Zuccaro, Piergiorgio ; Mombelli, Giuliana ; Calabresi, Laura ; Baldassarre, Damiano ; Palmi, Ilaria ; Sirtori, Cesare R. / Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. In: Pharmacological Research. 2007 ; Vol. 55, No. 4. pp. 310-317.
@article{d4ff51a37cee46b1a96df131117ccdbe,
title = "Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin",
abstract = "Statin therapy, although generally well tolerated, leads not infrequently to significant subjective and at times objective adverse effects (AEs), mainly of a muscular nature. The genetic background of these AEs is not clear and possibly side effects and lipid lowering efficacy may be linked. Aim of the study was a detailed evaluation of CYP450 and apolipoprotein E gene polymorphisms in two large series of age-sex matched patients with and without muscular side effects to statins. In a Clinical Institution specialised in lipid-lipoprotein disorders, 50 statin treated patients were selected, with subjective or objective statin-associated myopathy, evaluated using standardized forms. These were sex and age matched with 50 statin-treated patients from the same Clinic, without any subjective or objective complaints. DNA samples for the evaluation of CYP450 genetic polymorphisms and apo E genotypes were collected in order to assess correlations with both genetic polymorphisms and AEs, as well as with therapeutic efficacy. None of the assessed CYP450 polymorphisms appeared to be related to an increased incidence of AEs. The CYP2D6 *1/*4 and *4/4* poor metabolizer (PM) status was associated to a higher efficacy of statins metabolized by this system and, in addition, the apo E2 genotype was, in this series, linked to increased HDL-C levels after therapy. Patients with statin associated myopathy are not characterized by significantly different genotypes for the CYP450s responsible for statin metabolism. On the other hand, CYP2D6 PM status is associated to an increased efficacy of statins metabolized by this system.",
keywords = "Apo E allele variants, Cholesteraemic response, CYP450, Enzyme polymophisms, Muscle toxicity, Statins",
author = "Piergiorgio Zuccaro and Giuliana Mombelli and Laura Calabresi and Damiano Baldassarre and Ilaria Palmi and Sirtori, {Cesare R.}",
year = "2007",
month = "4",
doi = "10.1016/j.phrs.2006.12.009",
language = "English",
volume = "55",
pages = "310--317",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "4",

}

TY - JOUR

T1 - Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin

AU - Zuccaro, Piergiorgio

AU - Mombelli, Giuliana

AU - Calabresi, Laura

AU - Baldassarre, Damiano

AU - Palmi, Ilaria

AU - Sirtori, Cesare R.

PY - 2007/4

Y1 - 2007/4

N2 - Statin therapy, although generally well tolerated, leads not infrequently to significant subjective and at times objective adverse effects (AEs), mainly of a muscular nature. The genetic background of these AEs is not clear and possibly side effects and lipid lowering efficacy may be linked. Aim of the study was a detailed evaluation of CYP450 and apolipoprotein E gene polymorphisms in two large series of age-sex matched patients with and without muscular side effects to statins. In a Clinical Institution specialised in lipid-lipoprotein disorders, 50 statin treated patients were selected, with subjective or objective statin-associated myopathy, evaluated using standardized forms. These were sex and age matched with 50 statin-treated patients from the same Clinic, without any subjective or objective complaints. DNA samples for the evaluation of CYP450 genetic polymorphisms and apo E genotypes were collected in order to assess correlations with both genetic polymorphisms and AEs, as well as with therapeutic efficacy. None of the assessed CYP450 polymorphisms appeared to be related to an increased incidence of AEs. The CYP2D6 *1/*4 and *4/4* poor metabolizer (PM) status was associated to a higher efficacy of statins metabolized by this system and, in addition, the apo E2 genotype was, in this series, linked to increased HDL-C levels after therapy. Patients with statin associated myopathy are not characterized by significantly different genotypes for the CYP450s responsible for statin metabolism. On the other hand, CYP2D6 PM status is associated to an increased efficacy of statins metabolized by this system.

AB - Statin therapy, although generally well tolerated, leads not infrequently to significant subjective and at times objective adverse effects (AEs), mainly of a muscular nature. The genetic background of these AEs is not clear and possibly side effects and lipid lowering efficacy may be linked. Aim of the study was a detailed evaluation of CYP450 and apolipoprotein E gene polymorphisms in two large series of age-sex matched patients with and without muscular side effects to statins. In a Clinical Institution specialised in lipid-lipoprotein disorders, 50 statin treated patients were selected, with subjective or objective statin-associated myopathy, evaluated using standardized forms. These were sex and age matched with 50 statin-treated patients from the same Clinic, without any subjective or objective complaints. DNA samples for the evaluation of CYP450 genetic polymorphisms and apo E genotypes were collected in order to assess correlations with both genetic polymorphisms and AEs, as well as with therapeutic efficacy. None of the assessed CYP450 polymorphisms appeared to be related to an increased incidence of AEs. The CYP2D6 *1/*4 and *4/4* poor metabolizer (PM) status was associated to a higher efficacy of statins metabolized by this system and, in addition, the apo E2 genotype was, in this series, linked to increased HDL-C levels after therapy. Patients with statin associated myopathy are not characterized by significantly different genotypes for the CYP450s responsible for statin metabolism. On the other hand, CYP2D6 PM status is associated to an increased efficacy of statins metabolized by this system.

KW - Apo E allele variants

KW - Cholesteraemic response

KW - CYP450

KW - Enzyme polymophisms

KW - Muscle toxicity

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=34047136751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047136751&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2006.12.009

DO - 10.1016/j.phrs.2006.12.009

M3 - Article

C2 - 17289397

AN - SCOPUS:34047136751

VL - 55

SP - 310

EP - 317

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 4

ER -